<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272583</url>
  </required_header>
  <id_info>
    <org_study_id>DARE_2010</org_study_id>
    <nct_id>NCT01272583</nct_id>
  </id_info>
  <brief_title>Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery</brief_title>
  <acronym>DARE</acronym>
  <official_title>Effects of 6 Weeks Treatment With a Dipeptidyl Peptidase 4 Inhibitor on Counterregulatory and Incretin Hormones During Acute Hypoglycaemia in Patients With Type 1 Diabetes: a Randomized Double Blind Placebo-controlled Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory
      response to hypoglycaemia, with glucagon as the most important mediator, is initially
      diminished within a few years of onset of Type 1 diabetes and subsequently lost and thus
      increasing the risk of hypoglycaemia. Dipeptidyl Peptidase (DPP)-4 inhibitors augment the
      glucagon response to insulin-induced hypoglycaemia in type 2 diabetes. The investigators
      hypothesize that treatment with a DPP-4 inhibitor in patients with type 1 diabetes will
      recover the alpha cell response to hypoglycaemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 16 type 1 patients will be randomised to one of two treatment sequences: DPP-4 inhibitor
      followed by placebo or placebo followed by a DPP-4 inhibitor. Each treatment period lasts 6
      weeks, so all patients will receive treatment for 12 weeks in total. Induction of
      hypoglycaemia will take place at 0 weeks, 6 weeks and 12 weeks to determine the glucagon
      response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon Response to Acute Hypoglycaemia</measure>
    <time_frame>Change from initialisation phase to 40 minutes after onset of hypoglycaemia</time_frame>
    <description>Change in glucagon concentration from the initialisation phase to 40 minutes after occurrence of the autonomic reaction to hypoglycaemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucagon Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20 and 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intact and Total Glucagon Like Peptide-1 (GLP-1), Intact and Total Gastric Inhibitory Peptide (GIP) Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20, 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20, 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20, 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Hormone Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20, 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol Response to Acute Hypoglycaemia</measure>
    <time_frame>0, 10, 20, 40 minutes</time_frame>
    <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Hormone Responses to Acute Hypoglycaemia.</measure>
    <time_frame>Change from baseline symptomatic response at hypoglycaemia and 30 minutes after hypoglycaemia</time_frame>
    <description>The symptomatic responses to hypoglycaemia were assessed using a standard validated symptom questionnaire adapted for experimental hypoglycaemia (McCrimmon et al (2003) Diabet.Med. 20: 507-509). A 7-point Likert scale (1=symptom absent; 7=symptom experienced with great intensity) was used to score presence and intensity of autonomic and neuroglycopenic symptoms of hypoglycaemia. Symptom scores were obtained during the initialisation phase, at occurrence of autonomic reaction and again 30 minutes later. For analyses the scale was considered as a continuous variable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Sequence A (sitagliptin→placebo)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over, both arms reveived the same intervention in different order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B (placebo→sitagliptin)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cross-over, both arms reveived the same intervention in different order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg once daily for six weeks</description>
    <arm_group_label>Sequence A (sitagliptin→placebo)</arm_group_label>
    <arm_group_label>Sequence B (placebo→sitagliptin)</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, once daily for six weeks</description>
    <arm_group_label>Sequence A (sitagliptin→placebo)</arm_group_label>
    <arm_group_label>Sequence B (placebo→sitagliptin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus 5-20 years duration

          -  C-peptide negative

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Impaired awareness of hypoglycaemia

          -  BMI &gt; 27 kg/m2

          -  Evidence of severe diabetes complications (autonomic neuropathy, macroalbuminuria,
             proliferative retinopathy)

          -  Acute illness within 3 months before the study

          -  Significant renal impairment (creatinine clearance &lt; 50ml/min)

          -  Use of beta-adrenoreceptor blockers

          -  Cardiac history (previous arrhythmia)

          -  History of epilepsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frits Holleman, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1100DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>October 15, 2013</results_first_submitted>
  <results_first_submitted_qc>December 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2014</results_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>F Holleman</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>DPP-4 inhibitor</keyword>
  <keyword>Glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants came to the Academic Medical Center in Amsterdam for a screening visit to determine eligibility for the study.</recruitment_details>
      <pre_assignment_details>Patients were excluded if they were found to have impaired awareness of hypoglycaemia, had a history of seizures, cardiac arrhythmia (or used beta-adrenoreceptor blockers) and/or acute infection in the 12 weeks before the study, or evidence of severe diabetes complications (autonomic neuropathy, nephropathy or proliferative retinopathy).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A (Sitagliptin→Placebo)</title>
          <description>Cross-over, both arms reveived the same intervention in different order.
Sitagliptin : 100 mg once daily for six weeks
Placebo : placebo, once daily for six weeks</description>
        </group>
        <group group_id="P2">
          <title>Sequence B (Placebo→Sitagliptin)</title>
          <description>Cross-over, both arms reveived the same intervention in different order.
Sitagliptin : 100 mg once daily for six weeks
Placebo : placebo, once daily for six weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence A (Sitagliptin→Placebo)</title>
          <description>Cross-over, both arms reveived the same intervention in different order.
Sitagliptin : 100 mg once daily for six weeks
Placebo : placebo, once daily for six weeks</description>
        </group>
        <group group_id="B2">
          <title>Sequence B (Placebo→Sitagliptin)</title>
          <description>Cross-over, both arms reveived the same intervention in different order.
Sitagliptin : 100 mg once daily for six weeks
Placebo : placebo, once daily for six weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="26.3-39" lower_limit="26.3" upper_limit="39"/>
                    <measurement group_id="B2" value="33.5" spread="27.8-40.8" lower_limit="27.8" upper_limit="40.8"/>
                    <measurement group_id="B3" value="31.5" spread="27.0-40.0" lower_limit="27.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucagon Response to Acute Hypoglycaemia</title>
        <description>Change in glucagon concentration from the initialisation phase to 40 minutes after occurrence of the autonomic reaction to hypoglycaemia</description>
        <time_frame>Change from initialisation phase to 40 minutes after onset of hypoglycaemia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Response to Acute Hypoglycaemia</title>
          <description>Change in glucagon concentration from the initialisation phase to 40 minutes after occurrence of the autonomic reaction to hypoglycaemia</description>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="-0.67" upper_limit="2.67"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.67" upper_limit="2.67"/>
                    <measurement group_id="O3" value="1.33" lower_limit="-1.00" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intact and Total Glucagon Like Peptide-1 (GLP-1), Intact and Total Gastric Inhibitory Peptide (GIP) Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20, 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Intact and Total Glucagon Like Peptide-1 (GLP-1), Intact and Total Gastric Inhibitory Peptide (GIP) Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>pmol*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GLP-1 intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="0.0000" upper_limit="15.50"/>
                    <measurement group_id="O2" value="43.50" lower_limit="12.00" upper_limit="81.50"/>
                    <measurement group_id="O3" value="4.500" lower_limit="0.0000" upper_limit="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLP-1 total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562.2" lower_limit="435.0" upper_limit="623.8"/>
                    <measurement group_id="O2" value="555.0" lower_limit="450.0" upper_limit="611.3"/>
                    <measurement group_id="O3" value="552.5" lower_limit="433.8" upper_limit="596.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIP intact</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.0" lower_limit="361.3" upper_limit="513.8"/>
                    <measurement group_id="O2" value="490.0" lower_limit="461.3" upper_limit="630.0"/>
                    <measurement group_id="O3" value="452.5" lower_limit="435.0" upper_limit="532.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIP total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.5" lower_limit="201.3" upper_limit="436.3"/>
                    <measurement group_id="O2" value="285.0" lower_limit="160.0" upper_limit="367.5"/>
                    <measurement group_id="O3" value="342.5" lower_limit="238.8" upper_limit="497.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>GLP-1 intact</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <p_value_desc>GLP-1 Total</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>GIP intact</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>GIP total</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epinephrine Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20, 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Epinephrine Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>nmol*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="31.1" upper_limit="62.5"/>
                    <measurement group_id="O2" value="32.6" lower_limit="17.0" upper_limit="65.0"/>
                    <measurement group_id="O3" value="58.7" lower_limit="34.8" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucagon Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20 and 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>pmol*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="90" upper_limit="215"/>
                    <measurement group_id="O2" value="125" lower_limit="20" upper_limit="215"/>
                    <measurement group_id="O3" value="120" lower_limit="85" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Norepinephrine Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20, 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Norepinephrine Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>nmol*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="52.5" upper_limit="88.1"/>
                    <measurement group_id="O2" value="62.5" lower_limit="44.9" upper_limit="73.0"/>
                    <measurement group_id="O3" value="62.3" lower_limit="49.1" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Hormone Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20, 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Growth Hormone Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>mU*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1299" lower_limit="313.5" upper_limit="2560"/>
                    <measurement group_id="O2" value="261.5" lower_limit="47" upper_limit="1499"/>
                    <measurement group_id="O3" value="1406" lower_limit="781" upper_limit="2626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Dunn's Multiple Comparison Test</method>
            <method_desc>Post Hoc testing</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cortisol Response to Acute Hypoglycaemia</title>
        <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
        <time_frame>0, 10, 20, 40 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cortisol Response to Acute Hypoglycaemia</title>
          <description>Area under the curve (AUC) from onset of the autonomic response to hypoglycaemia to 40 minutes after onset of the autonomic response. AUC values were calculated by the trapezoid method.</description>
          <units>mU*minutes/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14480" lower_limit="11300" upper_limit="17180"/>
                    <measurement group_id="O2" value="13190" lower_limit="10920" upper_limit="18680"/>
                    <measurement group_id="O3" value="14800" lower_limit="8985" upper_limit="19160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANOVA</method>
            <method_desc>The Friedman Test was used for ANOVA.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Hormone Responses to Acute Hypoglycaemia.</title>
        <description>The symptomatic responses to hypoglycaemia were assessed using a standard validated symptom questionnaire adapted for experimental hypoglycaemia (McCrimmon et al (2003) Diabet.Med. 20: 507-509). A 7-point Likert scale (1=symptom absent; 7=symptom experienced with great intensity) was used to score presence and intensity of autonomic and neuroglycopenic symptoms of hypoglycaemia. Symptom scores were obtained during the initialisation phase, at occurrence of autonomic reaction and again 30 minutes later. For analyses the scale was considered as a continuous variable.</description>
        <time_frame>Change from baseline symptomatic response at hypoglycaemia and 30 minutes after hypoglycaemia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Sitagliptin Treatment</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Hormone Responses to Acute Hypoglycaemia.</title>
          <description>The symptomatic responses to hypoglycaemia were assessed using a standard validated symptom questionnaire adapted for experimental hypoglycaemia (McCrimmon et al (2003) Diabet.Med. 20: 507-509). A 7-point Likert scale (1=symptom absent; 7=symptom experienced with great intensity) was used to score presence and intensity of autonomic and neuroglycopenic symptoms of hypoglycaemia. Symptom scores were obtained during the initialisation phase, at occurrence of autonomic reaction and again 30 minutes later. For analyses the scale was considered as a continuous variable.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Autonomic symptoms score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic symptoms score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.7" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.7" upper_limit="3.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Baseline</title>
        </group>
        <group group_id="E2">
          <title>Sitagliptin Treatment</title>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Josefine E. Schopman</name_or_title>
      <organization>Academic Medical Center</organization>
      <phone>+31 20 5669111</phone>
      <email>j.e.schopman@amc.uva.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

